Chargement des cours...
Prévisions
L'objectif de cours moyen des analystes est de 35,38 € (+25,86 %). La médiane est de 32,90 € (+17,04 %).
| Acheter |
8 |
| Conserver |
1 |
| Vendre |
0 |
Discussions dans la communauté
Il n'y a pas encore de discussion sur cet actif.
Lancer une discussionActualités Accéder au fil d'actualités
Alto Neuroscience presents broad, biomarker-based psychiatry pipeline
Alto Neuroscience showcased its clinical pipeline at the H.C. Wainwright conference, with ALTO-207 for treatment-resistant depression as the centerpiece. ALTO-207 is expected to enter Phase 3 in early 2027; top-line data from the ongoing Phase 2b study are anticipated in the second half of 2027. Two other Phase 2b programs, ALTO-300 (major depression) and ALTO-100 (bipolar depression), will also deliver important data in 2027 and could advance to Phase 3. Management emphasized a biomarker-driven precision strategy for better patient selection, improved study quality through stricter screening, a cash position described as “excellent,” and a partnership review for ALTO-101. » Plus sur de.investing.com
Alto Neuroscience reaches new all-time high at 35.42 USD
Alto Neuroscience shares rose to a record high of 35.42 USD, lifting the market capitalization to about 1.38 billion USD. Over the past 12 months the stock is up roughly 794% and year-to-date about 92.6%. InvestingPro analysis notes point to a possible overvaluation relative to fair value and an overbought RSI. Alto announced an equity placement of 100 million USD at 26.48 USD per share, published a Nature Medicine study supporting the mechanism of action of pramipexole, received a 55 USD price target from H.C. Wainwright, and appointed Dr. Andrew Miller to its board. » Plus sur de.investing.com
Alto Neuroscience hits record high and announces share placement
Alto Neuroscience’s stock climbed to an all-time high of $32.74 and is currently trading around $32.94, implying a market capitalization of about $1.25 billion. InvestingPro rates the stock as relatively overvalued after it rose 906.09% last year. Alto plans a share placement at $26.48 per share with expected gross proceeds of around $100 million and anticipates closing the transaction soon. H.C. Wainwright reaffirmed a buy recommendation with a $50.00 price target; the company also reported new positive study results supporting a mechanism of action, the appointment of Dr. Andrew Miller to the board, and the accelerated start of the Phase 2b study of ALTO-207. » Plus sur de.investing.com
Alto Neuroscience reaches record high at $29.34
Alto Neuroscience shares rose to an all‑time high of $29.34, bringing market capitalization to about $1.09 billion after a year-to-date gain of more than 840%. The company announced an equity offering of $100 million at $26.48 per share and expects the deal to close soon. A study in Nature Medicine showed that pramipexole significantly reduced anhedonia in patients with mood disorders; a Phase 2b trial of ALTO‑207 also started earlier than planned. H.C. Wainwright reiterated a buy rating with a $50.00 price target, and Dr. Andrew Miller was appointed to the board. » Plus sur de.investing.com
Alto Neuroscience places shares for around $100 million at $26.48 per share
Alto Neuroscience announced a committed direct offering of 3,776,436 common shares at $26.48 per share and expects gross proceeds of about $100 million. The offering price is near the 52-week high after the stock rose 918% last year. The company plans to use the proceeds to accelerate clinical development of ALTO-207, including a planned additional Phase 3 study in treatment‑resistant depression, and for general corporate purposes; EcoR1 Capital led the financing. Closing of the offering is expected on Tuesday, subject to customary conditions. » Plus sur de.investing.com
Données financières de l'entreprise
| (EUR) | septembre 2026 | YoY |
|---|---|---|
| Chiffre d'affaires | 0 | - |
| Bénéfice brut | 0 | - |
| Bénéfice net | -22,18 M | 83,55 % |
| EBITDA | -20,7 M | 81,76 % |
Données fondamentales
| Indicateur | Valeur |
|---|---|
Capitalisation boursière | 1,1 Md € |
Nombre d'actions | 39,24 M |
Plus haut/bas sur 52 semaines | 33,78 € - 9,73 € |
| Dividendes | Non |
Bêta | 1,16 |
Ratio P/E | -12,46 |
Ratio PEG | 1,31 |
Ratio P/B | 4,89 |
Ratio P/S | 0,00 |
Profil de l'entreprise
Alto Neuroscience, Inc. est une société biopharmaceutique au stade clinique qui exerce son activité dans le développement de médicaments en psychiatrie. La société développe l'ALTO-100 pour le traitement des patients atteints de trouble dépressif majeur (TDM) et de trouble de stress post-traumatique ; l'ALTO-300, une petite molécule agoniste mélatoninergique et antagoniste sérotoninergique aux propriétés antidépressives destinée au traitement des patients atteints de TDM ; et l'ALTO-101, un nouvel inhibiteur de la phosphodiestérase 4 à petite molécule destiné au traitement du déficit cognitif associé à la schizophrénie. Elle développe également l'ALTO-203, un nouvel agoniste inverse à petite molécule du récepteur de l'histamine H3 destiné au traitement des patients atteints de TDM présentant des niveaux élevés d'anhédonie, ainsi que l'ALTO-202, un antagoniste de la sous-unité GluN2B du récepteur NMDA, biodisponible par voie orale, à l'étude, destiné au traitement du TDM. En outre, la société développe de nouvelles combinaisons pharmacodynamiquement synergiques ainsi qu'une plateforme de biomarqueurs assistée par l'IA qui combine des sources d'informations sur l'activité cérébrale et le comportement des patients afin d'identifier les patients susceptibles de répondre aux nouveaux candidats médicaments. Alto Neuroscience, Inc. a été constituée en 2019 et son siège se trouve à Los Altos, en Californie.
| Nom | ALTO NEUROSC. DL-,0001. Aktie |
| PDG | Amit Etkin |
| Siège social | Mountain View,
ca États-Unis |
| Site web | |
| Industrie | Produits chimiques |
| Introduction en bourse | 02/02/2024 |
| Employés | 68 |
Deep Dive
Symboles boursiers
| Bourse | Symbole |
|---|---|
NYSE | ANRO |
